The 7 major food allergy markets reached a value of US$ 2,199.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 3,425.2 Million by 2034, exhibiting a growth rate (CAGR) of 4.11% during 2024-2034.
Report Attribute
|
Key Statistics
|
---|---|
Base Year | 2023 |
Forecast Years | 2024-2034 |
Historical Years |
2018-2023
|
Market Size in 2023
|
US$ 2,199.4 Million |
Market Forecast in 2034
|
US$ 3,425.2 Million |
Market Growth Rate 2024-2034
|
4.11% |
The food allergy market has been comprehensively analyzed in IMARC's new report titled "Food Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Food allergy refers to an immune system response that develops when the body mistakenly identifies a particular food as harmful and triggers an allergic reaction. This disease can manifest in various ways, ranging from mild to severe symptoms. The indications usually occur within minutes or up to a couple of hours after consuming the allergenic food. Individuals suffering from this ailment might experience itching, hives, eczema, swelling, nausea, vomiting, stomach cramps, tingling sensation in the mouth, diarrhea, abdominal pain, sneezing, runny or stuffy nose, wheezing, shortness of breath, rapid heartbeat, lightheadedness, headache, etc. Food allergies can be diagnosed through a combination of medical history, physical examination, and specialized investigations. Blood workups, such as enzyme-linked immunosorbent assays, are also utilized to measure the levels of various antibodies, like immunoglobulin E, in response to particular foods. The healthcare professional may further perform a skin prick test to determine a patient's specific allergen profile and confirm a diagnosis. In rare cases, an oral food challenge is used to check if an individual can tolerate the food without experiencing an allergic reaction.
The increasing cases of imbalance or malfunction in the immune system, which can trigger an allergic response, are primarily driving the food allergy market. In addition to this, the rising prevalence of disruptions in the gut barrier, such as enhanced intestinal permeability, that cause allergens to pass through more easily is also creating a positive outlook for the market. Moreover, the widespread adoption of sublingual immunotherapy over oral regimens on account of its reduced risk of gastrointestinal side effects with minimal preparation or patient discomfort, is further propelling the market growth. Apart from this, the escalating application of DNA vaccination, since it is designed to deliver specific genetic material, encoding allergenic proteins or peptides, directly into the cells, thereby improving the quality of life in individuals suffering from the illness, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of epinephrine auto-injectors, which work rapidly to reverse allergic reactions and prevent their progression, is expected to drive the food allergy market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the food allergy market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for food allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the food allergy market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current food allergy marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Palforzia | Nestlé |
Ligelizumab | Novartis |
ADP101 | Alladapt Immunotherapeutics |
Viaskin Milk | DBV Technologies |
VE416 | Vedanta Biosciences |
Omalizumab | Genentech/Novartis |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Food Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies